Oncology

Ambulatory pharmacists can address mental health gaps, tackle stigma and SDOH, and power collaborative care, improving adherence and patient quality of life.

During Hepatitis Awareness Month, learn why hepatitis B vaccination and one-time screening help prevent silent infection and cut liver cancer risk.

Optimizing biomarker testing workflows and pharmacist involvement can improve precision oncology decision-making in non–small cell lung cancer.

Jordan Hill, PharmD, BCOP, talks about the impact of the updated NCCN guidelines for triple negative breast cancer.

New NCCN updates make sacituzumab govitecan a preferred first-line option in metastatic TNBC. Jordan Hill, PharmD, BCOP, explains the impact.

Remote therapeutic monitoring (RTM) improves patient outcomes, reduces hospitalizations, and supports sustainable oncology care delivery.

Phase 3 MagnetisMM-5 trial data demonstrated that Elrexfio (elranatamab) significantly improved progression-free survival compared with standard-of-care therapy in patients with relapsed or refractory multiple myeloma.

Data from COA highlight operationalizing novel therapies in community cancer care.

Advanced therapy innovations are transforming cancer care but are outpacing delivery systems and community providers with specialty pharmacy support are the key to bridging the gap.

Emerging data regarding newly diagnosed AML found that the Endothelial Activation and Stress Index independently predicts early mortality and ICU admission during intensive induction chemotherapy.

The need for data-driven, multidisciplinary care and the critical role of pharmacists in managing the growing complexity of oncology treatment

Pharmacists are enabling the shift to outpatient bispecific antibody care through education, SOP development, and care coordination.

Cardinal Health’s 2026 Advanced Therapies Report found strong provider momentum for expanding advanced therapy administration into community settings.

COA 2026 reveals how bispecific antibodies transform lymphoma care—outpatient workflows, SOPs, and infection vigilance shape safe BTCE delivery.

Postate cancer care shifts toward personalized, team-based management in an increasingly complex therapeutic landscape.

Pharmacists are central to implementing bispecific antibody therapies through clinical expertise, operational leadership, and care coordination.

Pharmacists support evidence-based treatment decisions, coordinate multidisciplinary care, and optimize precision oncology outcomes.

Integrated EMR systems and coordinated pharmacy operations can streamline biomarker-driven treatment decisions and improve patient outcomes.

Pharmacists play a crucial role in the treatment of patients with chronic myeloid leukemia (CML) taking tyrosine kinase inhibitors.

Pharmacists can help standardize biomarker testing and improve access to targeted therapies in non–small cell lung cancer.

Pharmacists can help optimize TKI therapy in CML through education, adherence support, toxicity monitoring, and collaboration with care teams.

CAR T drives deep remissions in myeloma and lymphoma, but payers, staffing, and hospital partners shape timely community access.

Bispecific antibodies are reshaping multiple myeloma care through improved safety and expanded outpatient use.

The cellular FLICE-like inhibitory protein (cFLIP) is a critical regulator of extrinsic apoptosis and essential driver of diffuse large B-cell lymphoma pathogenesis.

Oncology pharmacists should weigh lung cancer and diet data, probing pesticides as a possible factor in young nonsmokers.

The emerging data suggest a potential adjunctive strategy to target microbial drivers of head and neck squamous cell carcinoma.